Pulmonx Corporation (NASDAQ:LUNG) was founded in 1995 and is headquartered in Redwood City, California (and Neuchâtel, Switzerland). It is a commercial-stage medical technology company for patients with severe emphysema (a chronic obstructive pulmonary disease (COPD)) Of patients provide minimally invasive treatment.
Pulmonx Corporation (LUNG):
Pulmonx Corporation is a global leader in interventional pulmonology, planning tools, and treatment of obstructive pulmonary disease. It is the manufacturer of Zephyr Endobronchial Valve (Zephyr endobronchial valve). Zephyr® Valve was granted breakthrough status and was approved by the FDA in June 2018 because, according to the FDA, “Zephyr® Valve represents a breakthrough technology because the device can reduce bronchoscope lung volume without surgery, and Brings related risks. Compared with the current standard of care, the device has important clinical significance, so its usability is in the best interests of patients.”
Pulmonx Corporation’s commercial product portfolio includes Zephyr Endobronchial Valve, and 100 scientific articles on the clinical benefits of Zephyr Valves have been published. It also includes:
- The Zephyr Valve
- StratX® Lung Analysis Platform
- The Chartis® Pulmonary Assessment System
Pulmonx Corporation provides minimally invasive treatment for patients with severe emphysema (a chronic obstructive pulmonary disease (COPD)). The company’s solution consists of Zephyr Endobronchial Valve (Zephyr Endobronchial Valve) and Chartis Pulmonary Assessment System (Chartis Pulmonary Assessment System). ) And StratX® Lung Analysis Platform (StratX® Lung Analysis Platform), designed to treat patients who still have severe emphysema, still have obvious symptoms, and are undesirable or unsuitable for surgery despite medical management.
Pulmonx Corporation estimates that the company’s solution can currently cover approximately 500,000 patients in the United States and 700,000 patients in certain international markets, which represents a global market opportunity of approximately US$12 billion.
Pulmonx Corporation (LUNG) investment:
Pulmonx Corporation (NASDAQ:LUNG) was listed on NASDAQ on 10/1/2020 IPO. The planned issue price is $14.00-$16.00, and the actual issue price is $19. It will issue 6.7 million shares and raise $127.3 million. BofA Securities/ Morgan Stanley Underwriting, joint Stifel/ Wells Fargo Securities/ Canaccord Genuity.